This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Foleno, B. D.
Right arrow Articles by Bush, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Foleno, B. D.
Right arrow Articles by Bush, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2007, p. 361-365, Vol. 51, No. 1
0066-4804/07/$08.00+0     doi:10.1128/AAC.01017-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

In Vitro Antibacterial Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457{triangledown}

Barbara D. Foleno,1* Darren Abbanat,1 Raul M. Goldschmidt,1 Robert K. Flamm,2,{dagger} Steve D. Paget,1 Glenda C. Webb,1 Ellyn Wira,1 Mark J. Macielag,1 and Karen Bush1

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey 08869,1 Focus Bio-Inova, Inc., Herndon, Virginia 201712

Received 14 August 2006/ Returned for modification 12 September 2006/ Accepted 30 October 2006

RWJ-416457, an investigational pyrrolopyrazolyl-substituted oxazolidinone, inhibited the growth of linezolid-susceptible staphylococci, enterococci, and streptococci at concentrations of ≤4 µg/ml, generally exhibiting two- to fourfold-greater potency than that of linezolid. Time-kill studies demonstrated bacteriostatic effects for both RWJ-416457 and linezolid.

* Corresponding author. Mailing address: Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ 08869. Phone: (908) 704-4212. E-mail: bfoleno{at}prdus.jnj.com.

{triangledown} Published ahead of print on 13 November 2006.

{dagger} Present address: Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ 08869.

Antimicrobial Agents and Chemotherapy, January 2007, p. 361-365, Vol. 51, No. 1
0066-4804/07/$08.00+0     doi:10.1128/AAC.01017-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Hilliard, J. J., Fernandez, J., Melton, J., Macielag, M. J., Goldschmidt, R., Bush, K., Abbanat, D. (2009). In Vivo Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457. Antimicrob. Agents Chemother. 53: 2028-2033 [Abstract] [Full Text]  
  • Livermore, D. M., Warner, M., Mushtaq, S., North, S., Woodford, N. (2007). In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and Enterococci. Antimicrob. Agents Chemother. 51: 1112-1114 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»